Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Hydroxyethyl Starch in Sodium Chloride
Overview
What is Hydroxyethyl Starch in Sodium Chloride?
6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.
Each 100 mL of the solution contains: Hydroxyethyl Starch 130/0.4............................................6 gSodium Chloride USP......................................................900 mgWater for Injection USP....................................................qs
In addition, as required sodium hydroxide may be added to adjust the final pH so the final solution pH is 4.0 to 5.5.
The electrolyte composition is as follows (mEq/L): Sodium 154, Chloride 154.
The calculated osmolarity is 308 mOsmol/L.
The hydroxyethyl starch contained in 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection is a synthetic colloid for use in plasma volume replacement. The chemical name of hydroxyethyl starch is poly(O-2-hydroxyethyl) starch. The structural formula of hydroxyethyl starch is
R = -H, -CHCHOHR = -H, -CHCHOH or glucose units
Not made with natural rubber latex, PVC or DEHP.
The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.
The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. [see ]
What does Hydroxyethyl Starch in Sodium Chloride look like?
What are the available doses of Hydroxyethyl Starch in Sodium Chloride?
500 mL EXCEL® Container. Each 100 mL contains 6 g hydroxyethyl starch 130/0.4 in isotonic sodium chloride injection.
What should I talk to my health care provider before I take Hydroxyethyl Starch in Sodium Chloride?
How should I use Hydroxyethyl Starch in Sodium Chloride?
6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection is indicated for the treatment and prophylaxis of hypovolemia in adults and children. It is not a substitute for red blood cells or coagulation factors in plasma.
The initial 10 to 20 mL should be infused slowly, keeping the patient under close observation due to possible anaphylactoid reactions. [see ]
What interacts with Hydroxyethyl Starch in Sodium Chloride?
Sorry No Records found
What are the warnings of Hydroxyethyl Starch in Sodium Chloride?
Sorry No Records found
What are the precautions of Hydroxyethyl Starch in Sodium Chloride?
Sorry No Records found
What are the side effects of Hydroxyethyl Starch in Sodium Chloride?
Sorry No records found
What should I look out for while using Hydroxyethyl Starch in Sodium Chloride?
Do not use hydroxyethyl starch (HES) products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in critically ill adult patients, including patients with sepsis due to increased risk of mortality and renal replacement therapy. ()
Do not use HES products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with severe liver disease. ()
Do not use HES products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with known hypersensitivity to hydroxyethyl starch. ()
Do not use HES products in clinical conditions with volume overload. ()
Do not use HES products in patients with pre-existing coagulation or bleeding disorders. ()
Do not use HES products in patients with renal failure with oliguria or anuria not related to hypovolemia. ()
Do not use HES products in patients receiving dialysis. ()
Do not use HES products in patients with severe hypernatremia or severe hyperchloremia. ()
Do not use HES products in patients with intracranial bleeding. ()
What might happen if I take too much Hydroxyethyl Starch in Sodium Chloride?
Overdosage can lead to overloading of the circulatory system (e.g. pulmonary edema). In this case, the infusion should be stopped immediately and if necessary, a diuretic should be administered. [see ]
How should I store and handle Hydroxyethyl Starch in Sodium Chloride?
Store at 15° to 25°C (59° to 77°F). Do not freeze.Storage in automated dispensing machines: Brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. Rotate stock frequently.Store at 15° to 25°C (59° to 77°F). Do not freeze.Storage in automated dispensing machines: Brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. Rotate stock frequently.Bioaches patch is supplied as Box of 15 patchs: 3 pouches each containing 5 patchesBox of 1 patch: 1 Pouch in one BoxBox of 30 patches: 6 pouches each containing 5 patches.Storage: Store below 25°C. Avoid direct sunlight.Bioaches patch is supplied as Box of 15 patchs: 3 pouches each containing 5 patchesBox of 1 patch: 1 Pouch in one BoxBox of 30 patches: 6 pouches each containing 5 patches.Storage: Store below 25°C. Avoid direct sunlight.Bioaches patch is supplied as Box of 15 patchs: 3 pouches each containing 5 patchesBox of 1 patch: 1 Pouch in one BoxBox of 30 patches: 6 pouches each containing 5 patches.Storage: Store below 25°C. Avoid direct sunlight.Bioaches patch is supplied as Box of 15 patchs: 3 pouches each containing 5 patchesBox of 1 patch: 1 Pouch in one BoxBox of 30 patches: 6 pouches each containing 5 patches.Storage: Store below 25°C. Avoid direct sunlight.Bioaches patch is supplied as Box of 15 patchs: 3 pouches each containing 5 patchesBox of 1 patch: 1 Pouch in one BoxBox of 30 patches: 6 pouches each containing 5 patches.Storage: Store below 25°C. Avoid direct sunlight.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection contains hydroxyethyl starch in a colloidal solution which expands plasma volume when administered intravenously. This effect depends on the mean molecular weight (130,000 daltons; range 110,000 - 150,000 daltons), the molar substitution by hydroxyethyl groups (0.4; range 0.38 - 0.45) on glucose units of the starch, the pattern of hydroxyethyl substitution (C/C ratio) of approximately 9:1, and the concentration (6%), as well as the dosage and infusion rate.
Hydroxyethyl starch is a derivative of thin boiling waxy corn starch, which mainly consists of a glucose polymer (amylopectin) predominantly composed of alpha-1-4-connected glucose units with several alpha-1-6-branches. Substitution of hydroxyethyl groups on the glucose units of the polymer reduces the normal degradation of amylopectin by alpha-amylase in the body. The low molar substitution (0.4) is the main pharmacological determinant for the beneficial effects of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection on pharmacokinetics, intravascular volume and hemodilution. To describe the molecular weight and molar substitution characteristics of the hydroxyethyl starch in 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, the compound is designated as hydroxyethyl starch 130/0.4.
Non-Clinical Toxicology
Do not use hydroxyethyl starch (HES) products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in critically ill adult patients, including patients with sepsis due to increased risk of mortality and renal replacement therapy. ()Do not use HES products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with severe liver disease. ()
Do not use HES products, including 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection, in patients with known hypersensitivity to hydroxyethyl starch. ()
Do not use HES products in clinical conditions with volume overload. ()
Do not use HES products in patients with pre-existing coagulation or bleeding disorders. ()
Do not use HES products in patients with renal failure with oliguria or anuria not related to hypovolemia. ()
Do not use HES products in patients receiving dialysis. ()
Do not use HES products in patients with severe hypernatremia or severe hyperchloremia. ()
Do not use HES products in patients with intracranial bleeding. ()
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Calcium channel blockers may also have an additive effect when given with atenolol (see
Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers.
Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.
Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta blockers.
Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.
Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
Anaphylactoid reactions (mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved. [see ]
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
515Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).